#United States #Atlanta #PSA #BIMZELX #AxSpA

Promising Long-Term Outcomes from BIMZELX Trials

At the recent ACR 2025 conference held in Atlanta, UCB, a leading biopharmaceutical company, unveiled encouraging three-year data from its Phase 3 trials involving BIMZELX (bimekizumab) used in adult patients suffering from active psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS). This innovative treatment continues to show remarkable results in maintaining inflammation control and enhancing the quality of life for these patients.

Sustained Improvements in Disease Control

The results demonstrated significant sustained improvements in various critical disease markers for PsA patients. Over the three-year period, patients showed consistent improvements across several domains, including peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis. Impressively, these improvements indicate effective long-term control of inflammation, which is crucial for maintaining joint and overall function.

Professor Laura Coates from the University of Oxford noted, "The challenge in treating PsA lies in its diverse nature; successful therapy should address multiple disease dimensions. Data from this research highlights the substantial sustained improvements achieved through BIMZELX across key disease areas, suggesting its potential benefits for a broad range of patients."

Long-term Disease Activity Management

Furthermore, the findings revealed that around 50% of patients with nr-axSpA and AS maintained their low disease activity status (ASDAS LDA) across all assessments over the three-year period. Professor Fabian Proft from Universitätsmedizin Berlin emphasized the significance of these results for the clinical management of axSpA, remarking that achieving and sustaining low disease activity is paramount for effective treatment.

With half of the patients retaining their ASDAS LDA status throughout the observation period, and over 75% of patients continuing to exhibit a favorable response, BIMZELX is proving to be a viable option for ensuring long-term disease control in patients with axSpA.

Real-world Observations and Quality of Life Improvements

In a complementary analysis focusing on the real-world effectiveness of BIMZELX, data from the ongoing SPEAK study indicated that patients reported early and rapid improvements in their quality of life metrics from just two weeks of treatment. Patients with PsA demonstrated significant improvements in the PsA Impact of Disease (PsAID-12) scores and various health-related quality of life metrics measured by the SF-36 tool, revealing enhanced overall health perceptions by the 24-week mark.

For those with nr-axSpA and AS, improvements were similarly noted, including notable enhancements in assessment scores relevant to health impacts associated with their condition. This affirms BIMZELX’s capacity not just to control inflammation but also to promote a more favorable life quality for patients living with these challenging diseases.

Conclusion and Future Directions

UCB plans to present 16 more abstracts on BIMZELX at ACR 2025, reinforcing its pledge to lead in rheumatology advancement. As efforts to innovate continue, the company remains focused on delivering effective solutions tailored to address the needs across the spectrum of rheumatic diseases. This revolutionary drug not only signifies hope for patients but also illustrates the importance of sustained inflammation control in chronic inflammatory conditions, ultimately aiming to improve patients' lives well into the future.

In summary, BIMZELX (bimekizumab) is solidifying its role as an essential therapy for patients with PsA, nr-axSpA, and AS, demonstrating a unique ability to provide long-term relief and enhance the quality of life, as evidenced by compelling three-year data presented at ACR 2025.